Increased patient participation and longer follow-up times are needed to confirm the efficacy and safety of anti-PD-1 antibody maintenance treatment of ES-SCLC after first-line chemotherapy combined with CIK cells. This evidence concerns the gene PDCD1 and small cell lung carcinoma.